Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biotechnology company's stock.
Separately, Northland Securities cut shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research note on Friday, January 6th.
Get
Nabriva Therapeutics alerts:
Nabriva Therapeutics Stock Up 10.7 %
NBRV opened at $1.76 on Thursday. The firm's 50-day simple moving average is $1.81 and its 200-day simple moving average is $3.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $13.50. The firm has a market cap of $53.93 million, a price-to-earnings ratio of -0.09 and a beta of 1.67.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The business had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Equities research analysts anticipate that Nabriva Therapeutics will post -17.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.23% of the stock is currently owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Read More
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biotechnology company's stock.
股票研究人員在股票新聞網開始報導 納布里瓦治療學 (NASDAQ: NBRV — 獲得評分) 在星期四向客戶和投資者發出的研究報告中。該公司對生物技術公司的股票設定了「持有」評級。
Separately, Northland Securities cut shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research note on Friday, January 6th.
另外，北國證券在 1 月 6 日（星期五）的研究報告中將 Nabriva 治療學的股份從「表現大市」評級降至「表現不佳」評級。
Get
Nabriva Therapeutics
alerts:
Nabriva Therapeutics Stock Up 10.7 %
NBRV opened at $1.76 on Thursday. The firm's 50-day simple moving average is $1.81 and its 200-day simple moving average is $3.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $13.50. The firm has a market cap of $53.93 million, a price-to-earnings ratio of -0.09 and a beta of 1.67.
NBRV 在周四開盤 1.76 美元。該公司的 50 天簡單移動平均線為 1.81 美元，其 200 天的簡單移動平均線為 3.47 美元。該公司的債務與權益比率為 0.02，快速比率為 1.40，流動比率為 2.20。納布里瓦治療學有十二個月低點 1.22 美元和十二個月高點 13.50 美元。該公司的市值為 5,393 萬美元，股價與收益比為 -0.09，測試版為 1.67。
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The business had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Equities research analysts anticipate that Nabriva Therapeutics will post -17.37 EPS for the current fiscal year.
納布里瓦治療學 (NASDAQ: NBRV — 獲取評級) 最近一次公佈其盈利業績週四, 11 月 10 日.該生物技術公司報告了本季度每股收益（4.21 美元），缺失分析師的共識估計為（4.03 美元）（0.18 美元）。該業務本季度的收入為 915 萬美元，而分析師估計為 1,068 萬美元。納布里瓦治療學的負淨利潤率為 133.25％，負資產回報率為 120.02％。股票研究分析師預計，納布里瓦治療學將在本會計年度發布 -17.37 每股盈利。
Institutional Inflows and Outflows
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.23% of the stock is currently owned by hedge funds and other institutional investors.
一名機構投資者最近提出了在 Nabriva 治療學股票的地位。根據該公司在最近向證券交易委員會提交的 13F 表格中，文藝復興技術有限責任公司在第二季度將其在納布里瓦治療學公司（NASDAQ：NBRV-獲得評級）的持股量增加了 102.1％。在期內，該基金擁有該生物科技公司股票 795,938 股股份後，再收購 402,144 股股份。文藝復興技術有限責任公司在最近一季度末擁有約 0.13％ 的納布里瓦治療學價值 145,000 美元。目前，該股票的 0.23％ 由對沖基金和其他機構投資者擁有。
Nabriva Therapeutics Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Theraptics Plc 是一家生物製藥公司，致力於治療嚴重感染的新型抗感染藥物的研究，開發和商業化。其產品管線包括利福霉素、聯盟和 BC-7013。該公司成立於 2005 年 10 月，總部位於愛爾蘭都柏林。
Read More
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 獲取有關納布里瓦治療學（NBRV）的研究報告的免費副本
- 床浴 & 超越是盤旋排水
- Allegro 微系統是定位良好的半導體股票
- 斯科茨奇蹟-格羅擊中底部，反轉在遊戲中
- 阿爾特里亞是一個巨大的經濟衰退股票，長期前景不確定
- 諾瓦克斯股價在 1 月份跳漲，而其他股票則下滑
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收納布里瓦治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nabriva 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
